CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Electroacupuncturedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00742170
NCT00742170Phase 2Completed
CompareCT.gov

Transdermal Electroacupuncture for Opioid Detoxification

Mclean Hospital·interventional·Posted Aug 27, 2008·Updated Oct 21, 2014

In Brief

A Phase 2 clinical trial evaluating Electroacupuncture for Opioid Dependency. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This single-blind, randomized clinical trial tests whether electroacupuncture, provided as an adjunctive treatment, improves outcomes among patients receiving inpatient opioid detoxification from opioids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Dependency
CountriesUnited States
CollaboratorsHarvard Medical School (HMS and HSDM)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2008
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.8 years ago

Interventions

Electroacupuncturedevice

Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.